MiR-134, Mediated by IRF1, Suppresses Tumorigenesis and Progression by Targeting VEGFA and MYCN in Osteosarcoma

Author(s):

Zhuo Ma, Kai Li, Peng Chen, Qizheng Pan, Xuyang Li and Guoqing Zhao*   Pages 1197 - 1208 ( 12 )

Abstract:

<P>Background: Osteosarcoma (OS) is a prevalent primary bone malignancy and its distal metastasis remains the main cause of mortality in OS patients. MicroRNAs (miRNAs) play critical roles during cancer metastasis. </P><P> Objective: Thus, elucidating the role of miRNA dysregulation in OS metastasis may provide novel therapeutic targets. </P><P> Methods: The previous study found a low miR-134 expression level in the OS specimens compared with paracancer tissues. Overexpression of miR-134 stable cell lines was established. Cell viability assay, cell invasion and migration assay and apoptosis assay were performed to evaluate the role of miR-134 in OS in vitro. </P><P> Results: We found that miR-134 overexpression inhibits cell proliferation, migration and invasion, and induces cell apoptosis in both MG63 and Saos-2 cell lines. Mechanistically, miR-134 targets the 3&#039;-UTR of VEGFA and MYCN mRNA to silence its translation, which was confirmed by luciferase-reporter assay. The real-time PCR analysis illustrated that miR-134 overexpression decreases VEGFA and MYCN mRNA levels. Additionally, the overexpression of VEGFA or MYCN can partly attenuate the effects of miR-134 on OS cell migration and viability. Furthermore, the overexpression of miR-134 dramatically inhibits tumor growth in the human OS cell line xenograft mouse model in vivo. Moreover, bioinformatic and luciferase assays indicate that the expression of miR-134 is regulated by Interferon Regulatory Factor (IRF1), which binds to its promoter and activates miR-134 expression. </P><P> Conclusion: Our study demonstrates that IRF1 is a key player in the transcriptional control of miR-134, and it inhibits cell proliferation, invasion and migration in vitro and in vivo via targeting VEGFA and MYCN.</P>

Keywords:

IRF1, miR-134, VEGFA, MYCN, osteosarcoma, tumorigenesis.

Affiliation:

China-Japan Union Hospital of Jilin University, Changchun City, Jilin Province, 130033, China-Japan Union Hospital of Jilin University, Changchun City, Jilin Province, 130033, China-Japan Union Hospital of Jilin University, Changchun City, Jilin Province, 130033, China-Japan Union Hospital of Jilin University, Changchun City, Jilin Province, 130033, China-Japan Union Hospital of Jilin University, Changchun City, Jilin Province, 130033, China-Japan Union Hospital of Jilin University, Changchun City, Jilin Province, 130033

Graphical Abstract:

Read Full-Text article